83 250

Cited 20 times in

Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905).

Kim, HR; Jung, KH; Im, SA; Im, YH; Kang, SY; Park, KH; Lee, S; Kim, SB; Lee, KH; Ahn, JS; Kim, SI; Sohn, JH
Annals of oncology : official journal of the European Society for Medical Oncology, 24(6):1485-1490, 2013
Journal Title
Annals of oncology : official journal of the European Society for Medical Oncology
BACKGROUND: This phase II neoadjuvant trial evaluated bevacizumab-docetaxel and carboplatin in triple-negative breast cancer.

PATIENTS AND METHODS: Women with hormone receptor- and human epidermal growth factor receptor 2 (HER2)-negative, stage II/III breast cancer received six cycles of 75 mg/m(2) docetaxel, carboplatin (AUC = 5) and 15 mg/kg bevacizumab every 21 days. The primary end point was pathological complete response (pCR) in breasts and axillary lymph nodes (ALN).

RESULTS: Forty-five patients were recruited from the Korean Cancer Study Group. The median age was 45 (range 30-72) years. ALNs were positive in 80% of patients (n = 36) at diagnosis. Overall, 98% of patients (n = 44) completed therapy and underwent surgery. The pCR rate was 42% (n = 19); clinical response rate 96% (n = 43); complete 13% (n = 6); partial 82% (n = 37); stable disease 2% (n = 1). Breast-conserving surgery was undertaken in 78% of patients (n = 35). Most frequent grade 3/4 adverse events were neutropenia (84%, n = 38) and febrile neutropenia (9%, n = 4). One patient experienced delayed wound healing after surgery.

CONCLUSIONS: Neoadjuvant bevacizumab, docetaxel and carboplatin resulted in an encouraging pCR rate and negligible wound healing problems after surgery.
MeSH terms
AdultAgedAntibodies, Monoclonal, Humanized/administration & dosageAntineoplastic Combined Chemotherapy Protocols/*administration & dosageBreast Neoplasms/*drug therapy/epidemiology/*surgeryCarboplatin/administration & dosageFemaleHumansMiddle AgedNeoadjuvant Therapy/*methodsRepublic of Korea/epidemiologyTaxoids/administration & dosageTreatment Outcome
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
AJOU Authors
강, 석윤
Full Text Link
Files in This Item:
fulltext not available.txtDownload
RIS (EndNote)
XLS (Excel)


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.